Skip to main content

Table 7 Clinical trials targeting LAG-3 expression as of March 2021

From: Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes

Antibody name

Targets

Clinical studies

Phase

Conditions

IMP321

LAG-3 Fusion Protein

NCT00732082

Phase I

Pancreatic neoplasms

NCT03252938

Phase I

Solid tumors

NCT00351949

Phase I

Stage IV renal cell Carcinoma

NCT03625323

Phase II

NSCLC, head and neck squamous cell carcinoma (HNSCC)

NCT04252768

Phase I

Metastatic breast cancer

NCT00349934

Phase I

Metastatic breast cancer

NCT02614833

Phase II

Adenocarcinoma breast

NCT04811027

Phase II

HNSCC

Relatlimab

LAG-3

NCT04080804

Phase II

HNSCC

NCT01968109

Phase I/IIa

Neoplasms

NCT02061761

Phase I/IIa

Hematologic neoplasms

NCT03610711

Phase II

Gastroesophageal cancer

NCT02658981

Phase I

Glioblastoma

NCT04150965

Phase I/II

Multiple myeloma

NCT03044613

Phase Ib

Gastric cancer, Esophageal cancer, gastroesophageal cancer

NCT04611126

Phase I

Metastatic ovarian cancer, metastatic fallopian tube cancer, peritoneal cancer

NCT03623854

Phase II

Chordoma

NCT03459222

Phase I/II

Advanced cancer

NCT02966548

Phase I

Cancer

NCT03662659

Phase II

Gastric cancer, cancer of the stomach, esophagogastric Junction

NCT03743766

Phase II

Melanoma

NCT04326257

Phase II

Squamous cell carcinoma of the head and neck

NCT04658147

Phase I

Hepatocellular carcinoma

NCT03607890

Phase II

Cancer

NCT04567615

Phase II

Hepatocellular carcinoma

NCT02519322

Phase II

Melanoma

NCT02060188

Phase II

Microsatellite unstable colorectal cancer

NCT03493932

Phase I

Glioblastoma

NCT02488759

Phase I/II

Advanced cancer

Sym022

LAG-3

NCT03489369

Phase I

Metastatic cancer

NCT04641871

Phase I

Metastatic cancer

NCT03311412

Phase I

Metastatic cancer

RO7247669

PD-1 × LAG-3

NCT04140500

Phase I

Solid tumors

NCT04785820

Phase II

Advanced or metastatic esophageal

Squamous cell carcinoma

REGN3767

LAG-3

NCT03005782

Phase I

Malignancies

TSR-033

LAG-3

NCT03250832

Phase I

Neoplasms

EMB-02

PD-1 × LAG-3

NCT04618393

Phase I/II

Advanced solid tumors

MGD013

PD-1 × LAG-3

NCT03219268

Phase I

Advanced solid tumors

NCT04082364

Phase II/III

Gastric cancer

NCT04634825

Phase II

Colorectal cancer

NCT04129320

Phase II/III

Head and neck cancer

FS118

PD-L1 × LAG-3

NCT03440437

Phase I/II

Advanced cancer

INCAGN02385

LAG-3

NCT04370704

Phase I/II

Melanoma

TSR-033

LAG-3

NCT02817633

Phase I

Neoplasms

LAG525

LAG-3

NCT03365791

Phase II

Advanced solid tumors, diffuse large B cell lymphoma

NCT03742349

Phase I

Triple negative breast cancer

NCT02460224

Phase I/II

Advanced solid tumors

XmAb-22841

CTLA-4 × LAG-3

NCT03849469

Phase I

Advanced solid tumors

EOC202

LAG-3 fusion protein

NCT03600090

Phase I

Advanced solid tumors

  1. NSCLC: non-small cell lung cancer; HNSCC: head and neck squamous cell carcinoma; LAG-3: lymphocyte activating 3; PD-L1: programmed death ligand 1; PD-1: programmed death 1; CTLA-4: cytotoxic T-lymphocyte antigen 4